Fulgent Genetics (NASDAQ:FLGT) Updates FY 2025 Earnings Guidance

Key Points

• Fulgent Genetics updated its FY 2025 earnings guidance, projecting an earnings per share of -0.350, which is better than the consensus estimate of -0.550, and revenue expectations of $320.0 million, exceeding the consensus of $310.7 million.
• Analysts have recently issued mixed ratings on Fulgent Genetics, with Piper Sandler maintaining a "neutral" rating and a price target of $23.00, while Raymond James Financial upgraded their target to $25.00 with an "outperform" rating.
• Fulgent Genetics’ stock experienced a 1.8% decline recently, currently trading at $17.18, amidst a challenging financial performance with a reported EPS of -$0.25 for the last quarter.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of -0.350--0.350 for the period, compared to the consensus earnings per share estimate of -0.550. The company issued revenue guidance of $320.0 million-$320.0 million, compared to the consensus revenue estimate of $310.7 million.

Fulgent Genetics Price Performance

NASDAQ:FLGT traded up $2.57 during trading hours on Tuesday, reaching $20.93. The company's stock had a trading volume of 818,244 shares, compared to its average volume of 365,702. The company has a market cap of $637.22 million, a price-to-earnings ratio of -12.60 and a beta of 0.83. The business's 50-day moving average is $19.62 and its 200-day moving average is $18.37. Fulgent Genetics has a one year low of $14.57 and a one year high of $25.00.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.30. Fulgent Genetics had a negative net margin of 16.83% and a negative return on equity of 2.26%. The firm had revenue of $81.80 million during the quarter, compared to analysts' expectations of $76.21 million. During the same period in the prior year, the company posted $0.15 EPS. The company's revenue was up 15.2% on a year-over-year basis. On average, sell-side analysts predict that Fulgent Genetics will post -0.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on FLGT shares. UBS Group raised shares of Fulgent Genetics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $20.00 to $30.00 in a research report on Tuesday. Piper Sandler lowered their target price on shares of Fulgent Genetics from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Monday. Finally, Raymond James Financial reissued an "outperform" rating and issued a $25.00 target price (up previously from $24.00) on shares of Fulgent Genetics in a report on Monday, May 5th.

Insider Activity

In other Fulgent Genetics news, COO Jian Xie sold 1,873 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $20.54, for a total transaction of $38,471.42. Following the sale, the chief operating officer owned 372,631 shares of the company's stock, valued at approximately $7,653,840.74. This represents a 0.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 33.11% of the company's stock.

Hedge Funds Weigh In On Fulgent Genetics

An institutional investor recently raised its position in Fulgent Genetics stock. Goldman Sachs Group Inc. grew its holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 28.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 202,820 shares of the company's stock after buying an additional 45,279 shares during the period. Goldman Sachs Group Inc. owned approximately 0.67% of Fulgent Genetics worth $3,428,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 48.06% of the company's stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.